Repetitive Transcranial Magnetic Stimulation as a Therapeutic and Probe in Schizophrenia: Examining the Role of Neuroimaging and Future Directions
Autor: | Stephen J Brandt, Martin H. Plawecki, Halimah Y Oral, Carla Arellano-Bravo, Tom A. Hummer, Michael M. Francis |
---|---|
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Neurology Schizophrenia (object-oriented programming) medicine.medical_treatment Neuroimaging Review Affect (psychology) behavioral disciplines and activities 03 medical and health sciences 0302 clinical medicine mental disorders medicine Humans Pharmacology (medical) Neuronavigation Pharmacology business.industry Brain Cognition Transcranial Magnetic Stimulation Transcranial magnetic stimulation Treatment Outcome 030104 developmental biology Brain stimulation Schizophrenia Neurology (clinical) Neurosurgery business Neuroscience 030217 neurology & neurosurgery Forecasting |
Zdroj: | Neurotherapeutics |
ISSN: | 1878-7479 1933-7213 |
DOI: | 10.1007/s13311-021-01046-1 |
Popis: | Schizophrenia is a complex condition associated with perceptual disturbances, decreased motivation and affect, and disrupted cognition. Individuals living with schizophrenia may experience myriad poor outcomes, including impairment in independent living and function as well as decreased life expectancy. Though existing treatments may offer benefit, many individuals still experience treatment resistant and disabling symptoms. In light of the negative outcomes associated with schizophrenia and the limitations in currently available treatments, there is a significant need for novel therapeutic interventions. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that can modulate the activity of discrete cortical regions, allowing direct manipulation of local brain activation and indirect manipulation of the target’s associated neural networks. rTMS has been studied in schizophrenia for the treatment of auditory hallucinations, negative symptoms, and cognitive deficits, with mixed results. The field’s inability to arrive at a consensus on the use rTMS in schizophrenia has stemmed from a variety of issues, perhaps most notably the significant heterogeneity amongst existing trials. In addition, it is likely that factors specific to schizophrenia, rather than the rTMS itself, have presented barriers to the interpretation of existing results. However, advances in approaches to rTMS as a biologic probe and therapeutic, many of which include the integration of neuroimaging with rTMS, offer hope that this technology may still play a role in improving the understanding and treatment of schizophrenia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-021-01046-1. |
Databáze: | OpenAIRE |
Externí odkaz: |